

REMARKS

This is a divisional application from U.S. Serial No. 09/138,985, in which a restriction requirement was issued on December 13, 1999, restricting the application to one of the following four groups:

- I. Claims 1 – 18 and 39 – 46, drawn to a homogenate or a vaccine or a combination vaccine or a kit prepared from cells of Neospora, classified in class 530, subclass 350;
- II. Claims 19 – 28, drawn to a method for preparing a vaccine comprising homogenizing cells from Neospora, classified in class 435, subclass 71.1;
- III. Claims 29 – 38, drawn to a method for protecting a mammal against neosporosis administering a vaccine, classified in class 514, subclass 12;
- IV. Claims 47 – 51, drawn to an antibody, classified in class 530, subclass 387.1.


In parent application 09/138,985, applicants elected group I, claims 1 - 18 and 39 - 46. This divisional application is filed to prosecute the invention of group III, claim 29-38.

Accordingly, applicants have hereinabove canceled claims 1-28 and 39-51 without prejudice to applicants' right to pursue the subject matter of the canceled claims in one or more continuation or divisional applications. Claims 29-38 are pending.

A favorable response is earnestly solicited.

Respectfully submitted,

Date: November 8, 2001


Jeffrey N. Myers
Attorney for Applicant(s)
Reg. No. 41,213

Pfizer, Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-5061